FDA accepts and grants priority review for Allergan’s AVYCAZ sNDA
This filing will add important new clinical data to the current label from two Phase 3 trials evaluating the safety and efficacy of AVYCAZ, in combination with metronidazole,
ProBio has entered into an exclusive worldwide licensing agreement with South Korean biotechnology firm AbTis to develop and commercialise an early-stage therapeutic antibody asset.
Results were presented at the Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. Data from the study support the advancement of cabotegravir, an integrase strand transfer inhibitor,
At Week 48, the F/TAF-based regimens were found to be statistically non-inferior to the F/TDF-based regimens, based on percentages of patients with HIV-1 RNA levels less than 50